Research programme: influenza virus replication inhibitors - OSI Pharmaceuticals/Sankyo

Drug Profile

Research programme: influenza virus replication inhibitors - OSI Pharmaceuticals/Sankyo

Alternative Names: Influenza virus replication inhibitors research programme - OSI Pharmaceuticals

Latest Information Update: 04 Jun 2002

Price : $50

At a glance

  • Originator Medical Research Council; OSI Pharmaceuticals; Sankyo
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Influenza virus infections

Most Recent Events

  • 04 Jun 2002 Discontinued - Preclinical for Influenza virus infections in Japan (unspecified route)
  • 04 Jun 2002 Discontinued - Preclinical for Influenza virus infections in United Kingdom (unspecified route)
  • 04 Jun 2002 Discontinued - Preclinical for Influenza virus infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top